Ken Griffin Kal Vista Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$9.46 - $15.39 $835,318 - $1.36 Million	88,300 Added 910.31%	98,000 $1.13 Million
Q2 2024 Aug 14, 2024	SELL	$10.35 - $12.49 $211,140 - $254,796	-20,400 Reduced 67.77%	9,700 $114,000
Q1 2024 May 15, 2024	SELL	$11.07 - $16.04 $12,177 - $17,644	-1,100 Reduced 3.53%	30,100 $356,000
Q4 2023 Feb 14, 2024	BUY	$7.58 - $12.25 $225,126 - $363,825	29,700 Added 1980.0%	31,200 $382,000
Q3 2023 Nov 14, 2023	BUY	$8.95 - $11.35 $13,424 - $17,025	1,500 New	1,500 $14,000
Q4 2022 Feb 14, 2023	BUY	$4.2 - $14.24 $55,860 - $189,392	13,300 New	13,300 $89,000

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $217M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.